LONDON: The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.
Fevipiprant, which is being developed by Novartis, reduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients, researchers said on Saturday. No serious adverse events were reported.
Larger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations. Novartis believes the medicine could be filed for regulatory approval in around 2019.
Pills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects. They have since been replaced by inhalers that deliver small amounts of drugs directly into the lungs.
The Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.
The latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.
At the same time, many drugmakers are developing improved asthma inhalers, including "smart" devices with sensors that monitor use.
-
Living with chronic pain? This simple technique may help -
Are your daily nasal decongestant sprays safe? Find out what experts say -
Why depression is more than 'just in your head' -
Study finds your morning coffee could help with type 2 diabetes -
Westfield Bondi Junction hero Inspector Amy Scott faces rare cancer diagnosis -
Blood pressure medication linked with suicide risk? New study explains -
Cold weather may worsen urinary problems, physicians warn -
Daily fish oil supplements intake may reduce cardiovascular risks, heart problems